Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer’s Disease

Abstract

Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase which participates in the regulation of multiple cellular processes. As a confirmed tumor suppressor, PP2A activity is downregulated in tumors and its re-activation can induce apoptosis of cancer cells. In the brains of Alzheimer’s disease (AD) patients, decreased PP2A activity also plays a key role in promoting tau hyperphosphorylation and Aβ generation. In this review, we discussed compounds aiming at modulating PP2A activity in the treatment of cancer or AD. The upstream factors that inactivate PP2A in diseases have not been fully elucidated and further studies are needed. It will help for the refinement and development of novel and clinically tractable PP2A-targeted compounds or therapies for the treatment of tumor and AD.

Keywords

protein phosphatase 2A / compounds / tumor / Alzheimer’s disease

References

[1] Chen MJ, Dixon JE, Manning G. Genomics and evolution of protein phosphatases. Sci Signal, 2017,10 (474). pii: eaag1796.

[2] IngebritsenTS, CohenP. The protein phosphatases involved in cellular regulation. 1. Classification and substrate specificities. Eur J Biochem, 1983, 132(2): 255-261

[3] ShiY. Serine/Threonine Phosphatases: Mechanism through Structure. Cell, 2009, 139(3): 468-484

[4] VoronkovM, BraithwaiteSP, StockJB. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer’s disease. Future Med Chem, 2011, 3(7): 821-833

[5] SangodkarJ, FarringtonCC, McClinchK, et al.. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J, 2016, 283(6): 1004-1024

[6] JanssensV, GorisJ. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J, 2001, 353(Pt3): 417-439

[7] ChoUS, XuW. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature, 2007, 445(7123): 53-57

[8] LiuR, WangJZ. Protein phosphatase 2A in Alzheimer’s disease. Pathophysiology, 2009, 16(4): 273-277

[9] JanssensV, GorisJ, Van HoofC. PP2A: the expected tumor suppressor. Curr Opin Genet Dev, 2005, 15(1): 34-41

[10] LiuR, TianQ. Protein phosphatase 2A, a key player in Alzheimer’s disease. Front Med China, 2009, 3(1): 8-12

[11] NevianiP, SanthanamR, TrottaR, et al.. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 2005, 8(5): 355-368

[12] KalevP, SablinaAA. Protein phosphatase 2A as a potential target for anticancer therapy. Anticancer Agents Med Chem, 2011, 11(1): 38-46

[13] PerrottiD, NevianiP. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol, 2013, 14(6): e229-e238

[14] LonginS, ZwaenepoelK, LouisJV, et al.. Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic Subunit. J Biol Chem, 2007, 282(37): 26971-26980

[15] JacksonJB, PallasDC. Circumventing cellular control of PP2A by methylation promotes transformation in an Akt-dependent manner. Neoplasia, 2012, 14(7): 585-599

[16] JunttilaMR, PuustinenP, NiemelaM, et al.. CIP2A inhibits PP2A in human malignancies. Cell, 2007, 130(1): 51-62

[17] LiM, GuoH, DamuniZ. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry, 1995, 34(6): 1988-1996

[18] ZhangJ, YangPL, GrayNS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer, 2009, 9(1): 28-39

[19] KimSH, SeoMS, JeonWJ, et al.. Haloperidol regulates the phosphorylation level of the MEK-ERK-p90RSK signal pathway via protein phosphatase 2A in the rat frontal cortex. Int J Neuropsychopharmacol, 2008, 11(4): 509-517

[20] GutierrezA, PanL, GroenRW, et al.. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest, 2014, 124(2): 644-655

[21] SangodkarJ, PerlA, TohmeR, et al.. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest, 2017, 127(6): 2081-2090

[22] LiM, MakkinjeA, DamuniZ. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem, 1996, 271(19): 11 059-11 062

[23] MukhopadhyayA, SaddoughiSA, SongP, et al.. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J, 2009, 23(3): 751-763

[24] SaddoughiSA, GencerS, PetersonYK, et al.. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med, 2013, 5(1): 105-121

[25] ChristensenDJ, ChenY, OddoJ, et al.. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood, 2011, 118(15): 4150-4158

[26] JanghorbanM, FarrellAS, Allen-PetersenBL, et al.. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci, 2014, 111(25): 9157-9162

[27] AgarwalA, MacKenzieRJ, PippaR, et al.. Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia. Clin Cancer Res, 2014, 20(8): 2092-2103

[28] LiuZ, MaL, WenZS, et al.. Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis, 2014, 35(4): 905-914

[29] ComeC, LaineA, ChanrionM, et al.. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res, 2009, 15(16): 5092-5100

[30] KhannaA, BockelmanC, HemmesA, et al.. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst, 2009, 101(11): 793-805

[31] CorsonTW, CrewsCM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell, 2007, 130(5): 769-774

[32] ShrivastavaS, JeengarMK, ReddyVS, et al.. Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. Exp Mol Pathol, 2015, 98(3): 313-327

[33] MouH, ZhengY, ZhaoP, et al.. Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways. Toxicol In Vitro, 2011, 25(5): 1027-1032

[34] YuX, ZhouX, FuC, et al.. Celastrol induces apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway. Oncol Rep, 2015, 34(3): 1129-1136

[35] LeeJH, WonYS, ParkKH, et al.. Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT signaling. Apoptosis, 2012, 17(12): 1275-1286

[36] LiuZ, MaL, WenZ, et al.. Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells. ACS Med Chem Lett, 2014, 5(2): 113-118

[37] MiaoF, YangX, ZhouL, et al.. Structural modification of sanguinarine and chelerythrine and their antibacterial activity. Nat Prod Res, 2011, 25(9): 863-875

[38] HommaT, FujiiJ. An SOD1 deficiency aggravates proteasome inhibitor bortezomib-induced testicular damage in mice. Biochim Biophys Acta Gen Subj, 2019, 1863(6): 1108-1115

[39] YuHC, HouDR, LiuCY, et al.. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. PLoS One, 2013, 8(2): e55705

[40] TsengLM, LiuCY, ChangKC, et al.. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res, 2012, 14(2): R68

[41] UmemuraS, YoshidaS, OhtaY, et al.. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci, 2007, 98(12): 1889-1892

[42] ChaoTT, WangCY, LaiCC, et al.. TD-19, an Erlotinib Derivative, Induces Epidermal Growth Factor Receptor Wild-Type Nonsmall-Cell Lung Cancer Apoptosis through CIP2A-Mediated Pathway. J Pharmacol Exp Ther, 2014, 351(2): 352-358

[43] YuH, HungM, ChenY, et al.. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Dis, 2014, 5(7): e1359

[44] ConnorCM, PerlA, LeonardD, et al.. Therapeutic targeting of PP2A. Int J Biochem Cell Biol, 2018, 96: 182-193

[45] ChenK, PaoK, SuJ, et al.. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem, 2012, 20(20): 6144-6153

[46] YuHC, ChenHJ, ChangYL, et al.. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol, 2013, 85(3): 356-366

[47] LiuC, HuangT, HuangC, et al.. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. Eur J Cancer, 2017, 72: 112-123

[48] ChungV, MansfieldAS, BraitehF, et al.. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. Clin Cancer Res, 2017, 23(13): 3277-3284

[49] WangS, XieW, WangD, et al.. Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia. Oncotarget, 2015, 6(14): 12128-12140

[50] GlennerGG, WongCW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun, 1984, 120(3): 885-890

[51] Grundke-IqbalI, IqbalK, QuinlanM, et al.. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem, 1986, 261(13): 6084-6089

[52] IqbalK, Grundke-IqbalI, ZaidiT, et al.. Defective brain microtubule assembly in Alzheimer’s disease. Lancet, 1986, 2(8504): 421-426

[53] WangJ, XiaY, Grundke-IqbalI, et al.. Abnormal Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of Neurofibrillary Degeneration. J Alzheimers Dis, 2012, 33(s1): S123-S139

[54] Grundke-IqbalI, IqbalK, TungYC, et al.. Abnormal phosphorylation of the microtubule-associated protein X (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA, 1986, 83(13): 4913-4917

[55] GongCX, ShaikhS, WangJZ, et al.. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem, 1995, 65(2): 732-738

[56] TanimukaiH, KudoT, TanakaT, et al.. Novel therapeutic strategies for neurodegenerative disease. Psychogeriatrics, 2009, 9(2): 103-109

[57] ChoJH, JohnsonGV. Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem, 2004, 279(52): 54716-54723

[58] Vogelsberg-RagagliaV, SchuckT, TrojanowskiJQ, et al.. PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease hippocampus. Exp Neurol, 2001, 168(2): 402-412

[59] SontagE, LuangpiromA, HladikC, et al.. Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol, 2004, 63(4): 287-301

[60] GongCX, SinghTJ, Grundke-IqbalI, et al.. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem, 1993, 61(3): 921-927

[61] WangJ, TungYC, WangY, et al.. Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett, 2001, 507(1): 81-87

[62] LiuF, Grundke-IqbalI, IqbalK, et al.. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci, 2005, 22(8): 1942-1950

[63] LeeMS, KaoSC, LemereCA, et al.. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol, 2003, 163(1): 83-95

[64] ColomboA, BastoneA, PloiaC, et al.. JNK regulates APP cleavage and degradation in a model of Alzheimer’s disease. Neurobiol Dis, 2009, 33(3): 518-525

[65] BraithwaiteSP, SchmidRS, HeDN, et al.. Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer’s disease. Neurobiol Dis, 2010, 39(3): 311-317

[66] DhanasekaranDN, ReddyEP. JNK signaling in apoptosis. Oncogene, 2008, 27(48): 6245-6251

[67] SontagE, Nunbhakdi-CraigV, SontagJM, et al.. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci, 2007, 27(11): 2751-2759

[68] St-Cyr GiguèreF, AttioriE S, ChagnielL, et al.. The sphingosine-1-phosphate receptor 1 agonist SEW2871 reduces Tau-Ser262 phosphorylation in rat hippocampal slices. Brain Res, 2017, 1658: 51-59

[69] MizugishiK, YamashitaT, OliveraA, et al.. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol, 2005, 25(24): 11 113-11 121

[70] DomiseM, DidierS, MarinangeliC, et al.. AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Sci Rep, 2016, 6: 26758

[71] IijimaK, GattA, Iijima-AndoK. Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer’s disease. Hum Mol Genet, 2010, 19(15): 2947-2957

[72] WangX, XiongY, YangY, et al.. A novel tacrine-dihydropyridine hybrid (−) SCR1693 induces tau dephosphorylation and inhibits Aβ generation in cells. Eur J Pharmacol, 2015, 754: 134-139

[73] XiaY, LiuR, ChenR, et al.. Novel Multipotent AChEI-CCB Attenuates Hyperhomocysteinemia-Induced Memory Deficits and Neuropathologies in Rats. J Alzheimers Dis, 2014, 42(3): 1029-1039

[74] MillerLM, WangQ, TelivalaTP, et al.. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer’s disease. J Struct Biol, 2006, 155(1): 30-37

[75] SuhSW, JensenKB, JensenMS, et al.. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer’s disease brains. Brain Res, 2000, 852(2): 274-278

[76] MezzarobaL, AlfieriDF, ColadoSA, et al.. The role of zinc, copper, manganese and iron in neurodegenerative diseases. Neurotoxicology, 2019, 74: 230-241

[77] XiongY, LuoD, WangX, et al.. Zinc binds to and directly inhibits protein phosphatase 2A in vitro. Neurosci Bull, 2015, 31(3): 331-337

[78] XiongY, JingXP, ZhouXW, et al.. Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation. Neurobiol Aging, 2013, 34(3): 745-756

[79] BeardJL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr, 2001, 131(2S–2): 568S-579S 580S

[80] TaoY, WangY, RogersJT, et al.. Perturbed iron distribution in Alzheimer’s disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. J Alzheimers Dis, 2014, 42(2): 679-690

[81] AmitT, Avramovich-TiroshY, YoudimMB, et al.. Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J, 2008, 22(5): 1296-1305

[82] LiuB, MoloneyA, MeehanS, et al.. Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem, 2011, 286(6): 4248-4256

[83] SalissouM, MahamanY, ZhuF, et al.. Methanolic extract of Tamarix Gallica attenuates hyperhomocysteinemia induced AD-like pathology and cognitive impairments in rats. Aging (Albany NY), 2018, 10(11): 3229-3248

[84] ZhangQ, XiaY, LuoH, et al.. Codonopsis pilosula Polysaccharide Attenuates Tau Hyperphosphorylation and Cognitive Impairments in hTau Infected Mice. Front Mol Neurosci, 2018, 11: 437

[85] ZengK, LiM, HuJ, et al.. Ginkgo biloba Extract EGb761 Attenuates Hyperhomocysteinemia-induced AD Like Tau Hyperphosphorylation and Cognitive Impairment in Rats. Curr Alzheimer Res, 2018, 15(1): 89-99

[86] MahamanY, HuangF, WuM, et al.. Moringa Oleifera Alleviates Homocysteine-Induced Alzheimer’s Disease-Like Pathology and Cognitive Impairments. J Alzheimers Dis, 2018, 63(3): 1141-1159

[87] ChaiGS, JiangX, NiZF, et al.. Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. J Neurochem, 2013, 124(3): 388-396

[88] ZhangY, XieJZ, XuXY, et al.. Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting. Neurosci Bull, 2019, 35(4): 724-734

[89] ZhouP, ChenZ, ZhaoN, et al.. Acetyl-L-carnitine attenuates homocysteine-induced Alzheimer-like histopathological and behavioral abnormalities. Rejuvenation Res, 2011, 14(6): 669-679

[90] ZengP, ShiY, WangXM, et al.. Emodin Rescued Hyperhomocysteinemia-Induced Dementia and Alzheimer’s Disease-Like Features in Rats. Int J Neuropsychopharmacol, 2019, 22(1): 57-70

[91] WeiW, LiuYH, ZhangCE, et al.. Folate/vitamin-B12 prevents chronic hyperhomocysteinemia-induced tau hyperphosphorylation and memory deficits in aged rats. J Alzheimers Dis, 2011, 27(3): 639-650

[92] LeeKW, ChenW, JunnE, et al.. Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J Neurosci, 2011, 31(19): 6963-6971

[93] GueninS, SchwartzL, MorvanD, et al.. PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. Int J Oncol, 2008, 32(1): 49-57

[94] WuY, SongP, XuJ, et al.. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem, 2007, 282(13): 9777-9788

[95] YangX, YangY, FuZ, et al.. Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A. J Psychopharmacol, 2011, 25(8): 1118-1125

[96] ChoDH, ChoiYJ, JoSA, et al.. Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanismin volving protein phosphatase 2A-dependent p70 S6 kinase inhibition. Am J Physiol Cell Physiol, 2006, 291(2): C317-326

[97] LiuB, ArbogastLA. Progesterone decreases tyrosine hydroxylase phosphorylation state and increases protein phosphatase 2A activity in the stalk-median eminence on proestrous afternoon. J Endocrinol, 2010, 204(2): 209-219

[98] SwitzerCH, RidnourLA, ChengRY, et al.. Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene, 2009, 28(43): 3837-3846

[99] AcetoN, BertinoP, BarboneD, et al.. Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. Eur Respir J, 2009, 34(6): 1399-1407

[100] NevianiP, SanthanamR, TrottaR, et al.. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 2005, 8(5): 355-368

[101] PerrottiD, NevianiP. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1 (+) leukemias. Cancer Metastasis Rev, 2008, 27(2): 159-168

[102] NakashimaI, LiuW, AkhandAA, et al.. 4-hydroxynonenal triggers multistep signal transduction cascades for suppression of cellular functions. Mol Aspects Med, 2003, 24(4–5): 231-238

[103] LiuW, AkhandAA, TakedaK, et al.. Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal. Cell Death Differ, 2003, 10(7): 772-781

[104] KowluruA, SeaveySE, RabagliaME, et al.. Carboxylmethylation of the catalytic subunit of protein phosphatase 2A in insulin-secreting cells: evidence for functional consequences on enzyme activity and insulin secretion. Endocrinology, 1996, 137(6): 2315-2323

[105] KitanoK, NamKY, KimuraS, et al.. Sealing effects of (−)-epigallocatechin gallate on protein kinase C and protein phosphatase 2A. Biophys Chem, 1997, 65(2–3): 157-164

[106] de Los RíosC, EgeaJ, Marco-ContellesJ, et al.. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. J Med Chem, 2010, 53(14): 5129-5143